文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

HIV感染、HIV暴露未感染及未暴露儿童9和15-18月龄接种麻疹疫苗后4.5岁时的麻疹免疫力

Measles Immunity at 4.5 Years of Age Following Vaccination at 9 and 15-18 Months of Age Among Human Immunodeficiency Virus (HIV)-infected, HIV-exposed-uninfected, and HIV-unexposed Children.
PubMed 文献 · Clin Infect Dis · 2019-01-01

本研究评估HIV未暴露、HIV暴露未感染(HEU)及HIV感染儿童在9和15-18月龄接种麻疹疫苗后4.5岁时的抗体持久性。HIV感染儿童按随机分组在12月龄、24月龄或临床/免疫指征时中断ART。结果显示12和24月龄中断ART的HIV感染儿童麻疹抗体GMT和具有血清保护滴度的比例显著低于HIV未暴露儿童,而按指征中断ART组和HEU组与未暴露组相似。

要点

  • 12或24月龄中断ART的HIV感染儿童4.5岁时麻疹抗体GMT显著低于HIV未暴露儿童。
  • 上述中断ART组具有保护性抗体滴度(≥330 mIU/mL)的比例也显著降低。
  • 按指征中断ART组和HEU组的抗体水平与HIV未暴露儿童相似。

核心结论

  • 12或24月龄中断ART的HIV感染儿童在4.5岁时麻疹抗体GMT和血清保护比例显著低于HIV未暴露儿童,提示ART中断可能存在不利影响。

研究设计与样本

  • 研究纳入HIV未暴露(n=95)、HEU(n=84)、HIV/Immed-ART-12(n=70)、HIV/Immed-ART-24(n=70)和HIV/Def-ART(n=62)儿童,均在9和15-18月龄接种麻疹疫苗,于4.5岁时用ELISA定量抗麻疹血清IgG滴度。
  • HIV/Def-ART组启动ART的中位年龄为5.8月龄(IQR 4.4-10.3)。

主要发现

  • 与HIV未暴露儿童(2860 mIU/mL)相比,麻疹抗体GMT在HIV/Immed-ART-12组(571;P < .001)和HIV/Immed-ART-24组(1136;P < .001)显著更低,而HIV/Def-ART组(2777)和HEU组(3242)相似。
  • 与HIV未暴露儿童相比,抗体滴度≥330 mIU/mL(假定保护性血清相关指标;99%)的比例在HIV/Immed-ART-12组(70%;P < .001)和HIV/Immed-ART-24组(83%;P < .001)显著更低,而HIV/Def-ART组(90%)和HEU组(98%)相似。

关键数值与推荐

  • 麻疹抗体保护性血清相关指标为≥330 mIU/mL(原文假定保护性;99%)。
  • HIV未暴露儿童GMT为2860 mIU/mL,HIV/Immed-ART-12为571 mIU/mL,HIV/Immed-ART-24为1136 mIU/mL,HIV/Def-ART为2777 mIU/mL,HEU为3242 mIU/mL。
  • 抗体滴度≥330 mIU/mL的比例:HIV未暴露99%,HIV/Immed-ART-12 70%,HIV/Immed-ART-24 83%,HIV/Def-ART 90%,HEU 98%。

临床怎么用

  • 对于HIV感染儿童,应避免不必要的ART中断,以维持麻疹疫苗的长期免疫保护。
  • HEU儿童和按指征启动ART的HIV感染儿童在4.5岁时麻疹抗体水平与未暴露儿童相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Human immunodeficiency virus (HIV)-infected and HIV-exposed-uninfected (HEU) children may be at increased risk of measles infection due to waning of immunity following vaccination. We evaluated persistence of antibodies to measles vaccination at 4.5 years of age in HIV-unexposed, HEU, and HIV-infected children with CD4+ ≥25% previously randomized to immediate antiretroviral therapy (ART) interrupted at 12 months (HIV/Immed-ART-12), 24 months (HIV/Immed-ART-24), or when clinically/immunologically indicated (HIV/Def-ART). The HIV/Def-ART group initiated ART by median 5.8 (interquartile range, 4.4-10.3) months of age. METHODS: In this study, HIV-unexposed (n = 95), HEU (n = 84), HIV/Immed-ART-12 (n = 70), HIV/Immed-ART-24 (n = 70), and HIV/Def-ART (n = 62) children were scheduled to receive measles vaccination at age 9 and 15-18 months. Antimeasles serum immunoglobulin G titers were quantified using enzyme-linked immunosorbent assay at 4.5 years. RESULTS: Compared with HIV-unexposed children (2860 mIU/mL), measles antibody geometric mean titers (GMTs) were significantly lower in both HIV/Immed-ART-12 (571; P < .001) and HIV/Immed-ART-24 (1136; P < .001) but similar in the HIV/Def-ART (2777) and HEU (3242) groups. Furthermore, compared with HIV-unexposed, antibody titers ≥330 mIU/mL (ie, presumed serocorrelate for protection; 99%) were also significantly lower in HIV/Immed-ART-12 (70%; P < .001) and HIV/Immed-ART-24 (83%; P < .001) but similar in the HIV/Def-ART (90%) and HEU (98%) groups. CONCLUSIONS: HIV-infected children in whom ART was interrupted at either 12 or 24 months had lower GMTs and lower proportions with seroprotective titers than HIV-unexposed children, indicating a potential downside of ART treatment interruption. CLINICAL TRIALS REGISTRATION: NCT00099658 and NCT00102960.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mutsaerts EAML, Nunes MC, van Rijswijk MN, et al. Measles Immunity at 4.5 Years of Age Following Vaccination at 9 and 15-18 Months of Age Among Human Immunodeficiency Virus (HIV)-infected, HIV-exposed-uninfected, and HIV-unexposed Children. Clin Infect Dis. 2019. PMID: 30418528. doi:10.1093/cid/ciy964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。